Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Bristol Myers Squibb Drug Patent Portfolio

Bristol Myers Squibb owns 11 orange book drugs protected by 74 US patents with Baraclude having the least patent protection, holding only 2 patents. And Revlimid with maximum patent protection, holding 30 patents. Given below is the list of Bristol Myers Squibb's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9732062 Therapeutically active compounds and their methods of use 16 Sep, 2034
Active
US10093654 Therapeutically active compounds and their methods of use 01 Aug, 2034
Active
US9738625 Therapeutically active compounds and their methods of use 01 Aug, 2034
Active
US10294215 Therapeutically active compounds and their methods of use 07 Jan, 2033
Active
US9512107 Therapeutically active compositions and their methods of use 07 Jan, 2033
Active
US9326945 Apixaban formulations 24 Feb, 2031
Active
US10610125 Methods and compositions for cell-proliferation-related disorders 21 Jun, 2030
Active
US8741929 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas 08 Mar, 2028
Active
US7465800 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione 27 Apr, 2027
Active
US6967208 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors 21 Nov, 2026
Active
US7491725 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 28 Sep, 2026
Active
US7491725 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 28 Mar, 2026
Active
US8680103 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 04 Aug, 2025
Active
US8680103 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 04 Feb, 2025
Active
US7855217 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione 24 Nov, 2024 Expired
US7468363 Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023 Expired
US7968569 Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023 Expired
US8492406 Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023 Expired
US7135465 Sustained release beadlets containing stavudine 18 Aug, 2023 Expired
US8530498 Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione 15 May, 2023 Expired
US8648095 Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor 15 May, 2023 Expired
US9101621 Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation 15 May, 2023 Expired
US9101622 Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone 15 May, 2023 Expired
US9155730 Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent 15 May, 2023 Expired
US9393238 Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent 15 May, 2023 Expired
US7189740 Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes 11 Apr, 2023 Expired
US8404717 Methods of treating myelodysplastic syndromes using lenalidomide 11 Apr, 2023 Expired
US9056120 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine 11 Apr, 2023 Expired
US7135465 Sustained release beadlets containing stavudine 18 Feb, 2023 Expired
US6596746 Cyclic protein tyrosine kinase inhibitors 28 Dec, 2020 Expired
US7153856 Cyclic protein tyrosine kinase inhibitors 28 Oct, 2020 Expired
US6315720 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug 23 Oct, 2020 Expired
US6561977 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US6755784 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US8315886 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US8626531 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020 Expired
US7125875 Cyclic protein tyrosine kinase inhibitors 13 Oct, 2020 Expired
US6596746 Cyclic protein tyrosine kinase inhibitors 28 Jun, 2020 Expired
US7153856 Cyclic protein tyrosine kinase inhibitors 28 Apr, 2020 Expired
US7125875 Cyclic protein tyrosine kinase inhibitors 13 Apr, 2020 Expired
US6303146 Solid oral dosage form comprising a combination of metformin and glibenclamide 14 Jan, 2020 Expired
US6413980 Nitrogen containing heterobicycles as factor Xa inhibitors 22 Dec, 2019 Expired
US6238695 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Oct, 2019 Expired
US6555133 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Oct, 2019 Expired
US5635517 Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines 04 Oct, 2019 Expired
US6303146 Solid oral dosage form comprising a combination of metformin and glibenclamide 14 Jul, 2019 Expired
US6087383 Bisulfate salt of HIV protease inhibitor 21 Jun, 2019 Expired
US6238695 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Apr, 2019 Expired
US6555133 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Apr, 2019 Expired
US6087383 Bisulfate salt of HIV protease inhibitor 21 Dec, 2018 Expired
US6045501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US6561976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US6908432 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US8204763 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US8589188 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018 Expired
US6639071 Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Aug, 2018 Expired
US6939964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jul, 2018 Expired
US6639071 Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Feb, 2018 Expired
US6939964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jan, 2018 Expired
US5849911 Antivirally active heterocyclic azahexane derivatives 20 Dec, 2017 Expired
US5849911 Antivirally active heterocyclic azahexane derivatives 20 Jun, 2017 Expired
US6281230 Isoindolines, method of use, and pharmaceutical compositions 24 Jul, 2016 Expired
US6555554 Isoindolines, method of use, and pharmaceutical compositions 24 Jul, 2016 Expired
US7119106 Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline 24 Jul, 2016 Expired
US8288415 Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione 24 Jul, 2016 Expired
US5206244 Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines 21 Aug, 2015 Expired
US5663169 Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Mar, 2015 Expired
US5206244 Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines 21 Feb, 2015 Expired
US5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Oct, 2014 Expired
US5663169 Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Sep, 2014 Expired
US5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Apr, 2014 Expired
US5519021 Benzoxazinones as inhibitors of HIV reverse transcriptase 21 Nov, 2013 Expired
US5519021 Benzoxazinones as inhibitors of HIV reverse transcriptase 21 May, 2013 Expired
US5811423 Benzoxazinones as inhibitors of HIV reverse transcriptase 07 Aug, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Bristol Myers Squibb.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 22 May, 2024 US9512107
Maintenance Fee Reminder Mailed
Critical
11 Mar, 2024 US9393238
Payment of Maintenance Fee, 8th Year, Large Entity 18 Oct, 2023 US9326945 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 09 Oct, 2023 US10610125
Payment of Maintenance Fee, 8th Year, Large Entity 29 Mar, 2023 US9155730
Payment of Maintenance Fee, 8th Year, Large Entity 25 Jan, 2023 US9101622 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 25 Jan, 2023 US9101621 (Litigated)
Termination or Final Written Decision 06 Jan, 2023 US10610125
Payment of Maintenance Fee, 12th Year, Large Entity 14 Dec, 2022 US7968569 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 30 Nov, 2022 US9056120
Payment of Maintenance Fee, 4th Year, Large Entity 09 Nov, 2022 US10294215
Petition Requesting Trial 23 Aug, 2022 US10610125
Petition Requesting Trial 15 Aug, 2022 US10610125
Payment of Maintenance Fee, 12th Year, Large Entity 08 Jun, 2022 US7855217 (Litigated)
Correspondence Address Change
Critical
03 Jun, 2022 US10610125


Bristol Myers Squibb's Drug Patent Litigations

Bristol Myers Squibb's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 07, 2015, against patent number US5635517. The petitioner Coalition for Affordable Drugs VI LLC, challenged the validity of this patent, with Celgene Corporation as the respondent. Click below to track the latest information on how companies are challenging Bristol Myers Squibb's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10610125 August, 2022 Terminated-Settled
(06 Jan, 2023)
Servier Pharmaceuticals LLC et al. Rigel Pharmaceuticals, Inc.
US7968569 September, 2018 Terminated-Denied
(14 Mar, 2019)
Celgene Corporation Alvogen Pine Brook LLC
US7189740 August, 2018 Terminated-Denied
(11 Feb, 2019)
Celgene Corporation Dr. Reddy's Laboratories, Inc.
US8404717 August, 2018 Terminated-Denied
(11 Feb, 2019)
Celgene Corporation Dr. Reddy's Laboratories, Inc
US9056120 August, 2018 Terminated-Denied
(11 Feb, 2019)
Celgene Corporation Dr. Reddy's Laboratories, Inc.
US9326945 April, 2018 Terminated-Settled
(16 Jan, 2019)
Pfizer Inc. Mylan Pharmaceuticals Inc.
US8741929 February, 2018 Terminated-Denied
(27 Sep, 2018)
Celgene Corporation Apotex Inc.
US6045501 April, 2015 Final Written Decision
(26 Oct, 2016)
Celgene Corporation Coalition For Affordable Drugs VI LLC
US6315720 April, 2015 FWD Entered
(26 Oct, 2016)
Celgene Corporation Coalition for Affordable Drugs VI LLC
US6967208 August, 2015 Terminated-Denied
(22 Feb, 2016)
Bristol-Myers Squibb Company Coalition for Affordable Drugs IX, LLC
US5635517 May, 2015 Terminated-Denied
(16 Nov, 2015)
Celgene Corporation Coalition for Affordable Drugs VI LLC


Bristol Myers Squibb Drug Patents' Oppositions Filed in EPO

Bristol Myers Squibb drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 29, 2010, by Apotex Inc.. This opposition was filed on patent number EP05722772A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17175864A Aug, 2020 STADA Arzneimittel AG Granted and Under Opposition
EP17175864A Aug, 2020 Intas Pharmaceuticals Ltd. Granted and Under Opposition
EP17175864A Aug, 2020 Generics (U.K.) Limited Granted and Under Opposition
EP17175864A Aug, 2020 Wittkopp, Alexander Granted and Under Opposition
EP17175864A Aug, 2020 Alfred E. Tiefenbacher (GmbH & Co. KG) Granted and Under Opposition
EP17175864A Aug, 2020 von Seebach, Malte Granted and Under Opposition
EP17175864A Aug, 2020 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP17175864A Aug, 2020 Kutzenberger Wolff & Partner Granted and Under Opposition
EP17175864A Aug, 2020 Zentiva k.s. Granted and Under Opposition
EP17175864A Aug, 2020 Teva Pharmaceutical Industries LTD. Granted and Under Opposition
EP17175864A Aug, 2020 Krka, d.d., Novo mesto Granted and Under Opposition
EP17175864A Aug, 2020 SANDOZ AG Granted and Under Opposition
EP17175788A Jul, 2020 STADA Arzneimittel AG Granted and Under Opposition
EP17175788A Jul, 2020 Generics (U.K.) Limited Granted and Under Opposition
EP17178613A Jul, 2020 STADA Arzneimittel AG Granted and Under Opposition
EP17178613A Jul, 2020 Generics (U.K.) Limited Granted and Under Opposition
EP17175788A Jul, 2020 Intas Pharmaceuticals Ltd. Granted and Under Opposition
EP17175788A Jul, 2020 KRKA, d.d., Novo mesto Granted and Under Opposition
EP17175788A Jul, 2020 Sandoz AG Granted and Under Opposition
EP17178613A Jul, 2020 Sandoz AG Granted and Under Opposition
EP17178613A Jul, 2020 KRKA, d.d., Novo mesto Granted and Under Opposition
EP17178613A Jul, 2020 Intas Pharmaceuticals Ltd. Granted and Under Opposition
EP17178613A Jul, 2020 Medichem S.A. Granted and Under Opposition
EP17175788A Jul, 2020 Medichem S.A. Granted and Under Opposition
EP17175788A Jul, 2020 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP17178613A Jul, 2020 Teva Pharmaceutical Industries Ltd Granted and Under Opposition
EP17175788A Jul, 2020 Kutzenberger Wolff & Partner Granted and Under Opposition
EP17178613A Jul, 2020 Zentiva k.s. Granted and Under Opposition
EP17178613A Jul, 2020 Kutzenberger Wolff & Partner Granted and Under Opposition
EP17175788A Jul, 2020 Zentiva k.s. Granted and Under Opposition
EP17178613A Jul, 2020 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP17175788A Jul, 2020 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP15190823A Sep, 2019 STADA Arzneimittel AG Granted and Under Opposition
EP15190823A Sep, 2019 Generics (U.K.) Limited Granted and Under Opposition
EP15190823A Sep, 2019 Zentiva, k.s. Granted and Under Opposition
EP15190823A Sep, 2019 Intas Pharmaceuticals Ltd. Granted and Under Opposition
EP15190823A Sep, 2019 KRKA, d.d., Novo mesto Granted and Under Opposition
EP15190823A Sep, 2019 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Granted and Under Opposition
EP15190823A Aug, 2019 Hamm&Wittkopp Patentanwälte PartmbB Granted and Under Opposition
EP15190823A Aug, 2019 Sandoz AG Granted and Under Opposition
EP15190823A Aug, 2019 Teva Pharmaceutical Industries Ltd. Granted and Under Opposition
EP15199526A Aug, 2019 Generics [UK] Ltd Revoked
EP15199540A Aug, 2019 Generics (UK) Ltd Revoked
EP15199521A Aug, 2019 Hamm&Wittkopp Patentanwälte PartmbB Revoked
EP15199521A Aug, 2019 Bachelin, Martin, Dr. Revoked
EP15199521A Aug, 2019 Generics [UK] Ltd Revoked
EP15199521A Jul, 2019 Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB Revoked
EP15199521A Jul, 2019 Pruß, Timo Revoked
EP11707284A Sep, 2016 Zentiva k.s. Revoked
EP11707284A Sep, 2016 LEK Pharmaceuticals d.d. Revoked
EP11707284A Sep, 2016 Intas Pharmaceuticals Ltd. Revoked
EP11707284A Sep, 2016 Hamm&Wittkopp Patentanwälte PartmbB Revoked
EP11707284A Sep, 2016 Generics (U.K.) Limited Revoked
EP11707284A Sep, 2016 Galenicum Health S.L. Revoked
EP11707284A Sep, 2016 KRKA, d.d., Novo mesto Revoked
EP11707284A Sep, 2016 STADA Arzneimittel AG Revoked
EP11707284A Sep, 2016 Plougmann Vingtoft a/s Revoked
EP11707284A Sep, 2016 ZAKLADY FARMACEUTYCZNE POLPHARMA S.A. Revoked
EP11707284A Sep, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP09008756A Jul, 2015 Accord Healthcare Ltd Revoked
EP09008756A Jul, 2015 Hexal AG Revoked
EP09008756A Jul, 2015 Generics [UK] Limited (trading as Mylan) Revoked
EP09008756A Jul, 2015 Intellectual Property Services Revoked
EP09008756A Jul, 2015 Synthon B.V. Revoked
EP09008756A Jul, 2015 Actavis Group PTC EHF Revoked
EP04783095A Aug, 2012 Teva Pharmaceutical Industries Ltd. Revoked
EP04783095A Aug, 2012 Generics [UK] Limited Revoked
EP03728969A Dec, 2010 STRAWMAN LIMITED Revoked
EP03728969A Nov, 2010 Synthon B.V. Revoked
EP05722772A Sep, 2010 Gallafent, Antony Xavier Patent maintained as amended
EP05722772A Sep, 2010 APOTEX INC. Patent maintained as amended


Bristol Myers Squibb's Family Patents

Bristol Myers Squibb drugs have patent protection in a total of 58 countries. It's US patent count contributes only to 22.9% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Bristol Myers Squibb Drug List

Given below is the complete list of Bristol Myers Squibb's drugs and the patents protecting them.


1. Baraclude

Baraclude is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5206244
(Pediatric)
Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines 21 Aug, 2015
(9 years ago)
Expired
US5206244 Hydroxymethyl (methylenecyclopentyl) purines and pyrimidines 21 Feb, 2015
(9 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Baraclude's drug page


2. Eliquis

Eliquis is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9326945 Apixaban formulations 24 Feb, 2031
(6 years from now)
Active
US6967208 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors 21 Nov, 2026
(1 year, 11 months from now)
Active
US6413980 Nitrogen containing heterobicycles as factor Xa inhibitors 22 Dec, 2019
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Eliquis's drug page


3. Glucovance

Glucovance is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6303146
(Pediatric)
Solid oral dosage form comprising a combination of metformin and glibenclamide 14 Jan, 2020
(4 years ago)
Expired
US6303146 Solid oral dosage form comprising a combination of metformin and glibenclamide 14 Jul, 2019
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Glucovance's drug page


4. Idhifa

Idhifa is protected by 6 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9732062 Therapeutically active compounds and their methods of use 16 Sep, 2034
(9 years from now)
Active
US10093654 Therapeutically active compounds and their methods of use 01 Aug, 2034
(9 years from now)
Active
US9738625 Therapeutically active compounds and their methods of use 01 Aug, 2034
(9 years from now)
Active
US10294215 Therapeutically active compounds and their methods of use 07 Jan, 2033
(8 years from now)
Active
US9512107 Therapeutically active compositions and their methods of use 07 Jan, 2033
(8 years from now)
Active
US10610125 Methods and compositions for cell-proliferation-related disorders 21 Jun, 2030
(5 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Idhifa's drug page


5. Pravachol

Pravachol is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5622985
(Pediatric)
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Oct, 2014
(10 years ago)
Expired
US5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Apr, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pravachol's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Pravigard Pac (copackaged)

Pravigard Pac (copackaged) is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5622985
(Pediatric)
Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Oct, 2014
(10 years ago)
Expired
US5622985 Method for preventing a second heart attack employing an HMG CoA reductase inhibitor 22 Apr, 2014
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pravigard Pac (copackaged)'s drug page


7. Revlimid

Revlimid is protected by 30 patents, out of which 28 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8741929 Methods using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of mantle cell lymphomas 08 Mar, 2028
(3 years from now)
Active
US7465800 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione 27 Apr, 2027
(2 years from now)
Active
US7855217 Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione 24 Nov, 2024
(24 days ago)
Expired
US7468363 Methods for treatment of cancers using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023
(1 year, 2 months ago)
Expired
US7968569 Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023
(1 year, 2 months ago)
Expired
US8492406 Methods for treatment of follicular lymphoma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione 07 Oct, 2023
(1 year, 2 months ago)
Expired
US8530498 Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione 15 May, 2023
(1 year, 7 months ago)
Expired
US8648095 Methods for treating multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with proteasome inhibitor 15 May, 2023
(1 year, 7 months ago)
Expired
US9101621 Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation 15 May, 2023
(1 year, 7 months ago)
Expired
US9101622 Methods for treating newly diagnosed multiple myeloma 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with dexamethasone 15 May, 2023
(1 year, 7 months ago)
Expired
US9155730 Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent 15 May, 2023
(1 year, 7 months ago)
Expired
US9393238 Methods for treating non-hodgkin's lymphoma with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione in combination with a second active agent 15 May, 2023
(1 year, 7 months ago)
Expired
US7189740 Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes 11 Apr, 2023
(1 year, 8 months ago)
Expired
US8404717 Methods of treating myelodysplastic syndromes using lenalidomide 11 Apr, 2023
(1 year, 8 months ago)
Expired
US9056120 Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine 11 Apr, 2023
(1 year, 8 months ago)
Expired
US6315720 Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug 23 Oct, 2020
(4 years ago)
Expired
US6561977 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(4 years ago)
Expired
US6755784 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(4 years ago)
Expired
US8315886 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(4 years ago)
Expired
US8626531 Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated 23 Oct, 2020
(4 years ago)
Expired
US5635517 Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines 04 Oct, 2019
(5 years ago)
Expired
US6045501 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US6561976 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US6908432 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US8204763 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US8589188 Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug 28 Aug, 2018
(6 years ago)
Expired
US6281230 Isoindolines, method of use, and pharmaceutical compositions 24 Jul, 2016
(8 years ago)
Expired
US6555554 Isoindolines, method of use, and pharmaceutical compositions 24 Jul, 2016
(8 years ago)
Expired
US7119106 Pharmaceutical compositions of 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline 24 Jul, 2016
(8 years ago)
Expired
US8288415 Pharmaceutical compositions of 3-(4-amino-1-oxoisoindolin-2yl)-piperidine-2,6-dione 24 Jul, 2016
(8 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Revlimid's drug page


8. Reyataz

Reyataz is protected by 4 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6087383
(Pediatric)
Bisulfate salt of HIV protease inhibitor 21 Jun, 2019
(5 years ago)
Expired
US6087383 Bisulfate salt of HIV protease inhibitor 21 Dec, 2018
(5 years ago)
Expired
US5849911
(Pediatric)
Antivirally active heterocyclic azahexane derivatives 20 Dec, 2017
(7 years ago)
Expired
US5849911 Antivirally active heterocyclic azahexane derivatives 20 Jun, 2017
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Reyataz's drug page


9. Sprycel

Sprycel is protected by 10 patents, out of which 6 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7491725
(Pediatric)
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 28 Sep, 2026
(1 year, 9 months from now)
Active
US7491725 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 28 Mar, 2026
(1 year, 3 months from now)
Active
US8680103
(Pediatric)
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 04 Aug, 2025
(7 months from now)
Active
US8680103 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors 04 Feb, 2025
(a month from now)
Active
US6596746
(Pediatric)
Cyclic protein tyrosine kinase inhibitors 28 Dec, 2020
(3 years ago)
Expired
US7153856
(Pediatric)
Cyclic protein tyrosine kinase inhibitors 28 Oct, 2020
(4 years ago)
Expired
US7125875
(Pediatric)
Cyclic protein tyrosine kinase inhibitors 13 Oct, 2020
(4 years ago)
Expired
US6596746 Cyclic protein tyrosine kinase inhibitors 28 Jun, 2020
(4 years ago)
Expired
US7153856 Cyclic protein tyrosine kinase inhibitors 28 Apr, 2020
(4 years ago)
Expired
US7125875 Cyclic protein tyrosine kinase inhibitors 13 Apr, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sprycel's drug page


10. Sustiva

Sustiva is protected by 13 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6238695
(Pediatric)
Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Oct, 2019
(5 years ago)
Expired
US6555133
(Pediatric)
Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Oct, 2019
(5 years ago)
Expired
US6238695 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Apr, 2019
(5 years ago)
Expired
US6555133 Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants 06 Apr, 2019
(5 years ago)
Expired
US6639071
(Pediatric)
Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Aug, 2018
(6 years ago)
Expired
US6939964
(Pediatric)
Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jul, 2018
(6 years ago)
Expired
US6639071 Crystal Forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 14 Feb, 2018
(6 years ago)
Expired
US6939964 Crystal forms of (-)-6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one 20 Jan, 2018
(6 years ago)
Expired
US5663169
(Pediatric)
Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Mar, 2015
(9 years ago)
Expired
US5663169 Benzoxazinones as inhibitors of HIV reverse transcriptase 02 Sep, 2014
(10 years ago)
Expired
US5519021
(Pediatric)
Benzoxazinones as inhibitors of HIV reverse transcriptase 21 Nov, 2013
(11 years ago)
Expired
US5519021 Benzoxazinones as inhibitors of HIV reverse transcriptase 21 May, 2013
(11 years ago)
Expired
US5811423 Benzoxazinones as inhibitors of HIV reverse transcriptase 07 Aug, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sustiva's drug page


11. Zerit Xr

Zerit Xr is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7135465
(Pediatric)
Sustained release beadlets containing stavudine 18 Aug, 2023
(1 year, 4 months ago)
Expired
US7135465 Sustained release beadlets containing stavudine 18 Feb, 2023
(1 year, 9 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zerit Xr's drug page


Bristol Myers Squibb News

Regulatory Agency in the United States Greenlights Bristol Myers Squibb's Schizophrenia Medication

27 Sep, 2024

FDA is set to review the approval of the first new drug for schizophrenia in more than three decades

26 Sep, 2024

US Doctors Anticipate Changes in Lupus Treatments

17 Sep, 2024

Improving medication adherence and minimizing side effects through the development of prodrugs and patent protection

11 Sep, 2024

See More